Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Binding and functional profiling of antibody mutants guides selection of optimal candidates as antibody drug conjugates.

Zwaagstra JC, Sulea T, Baardsnes J, Radinovic S, Cepero-Donates Y, Robert A, O'Connor-McCourt MD, Tikhomirov IA, Jaramillo ML.

PLoS One. 2019 Dec 31;14(12):e0226593. doi: 10.1371/journal.pone.0226593. eCollection 2019.

2.

Structure-based engineering of pH-dependent antibody binding for selective targeting of solid-tumor microenvironment.

Sulea T, Rohani N, Baardsnes J, Corbeil CR, Deprez C, Cepero-Donates Y, Robert A, Schrag JD, Parat M, Duchesne M, Jaramillo ML, Purisima EO, Zwaagstra JC.

MAbs. 2020 Jan-Dec;12(1):1682866. doi: 10.1080/19420862.2019.1682866.

3.

Isolation of TGF-β-neutralizing single-domain antibodies of predetermined epitope specificity using next-generation DNA sequencing.

Henry KA, Hussack G, Collins C, Zwaagstra JC, Tanha J, MacKenzie CR.

Protein Eng Des Sel. 2016 Oct;29(10):439-443. doi: 10.1093/protein/gzw043. Epub 2016 Sep 8.

PMID:
27613412
4.

Engineering and therapeutic application of single-chain bivalent TGF-β family traps.

Zwaagstra JC, Sulea T, Baardsnes J, Lenferink AE, Collins C, Cantin C, Paul-Roc B, Grothe S, Hossain S, Richer LP, L'Abbé D, Tom R, Cass B, Durocher Y, O'Connor-McCourt MD.

Mol Cancer Ther. 2012 Jul;11(7):1477-87. doi: 10.1158/1535-7163.MCT-12-0060. Epub 2012 May 4.

5.

Transforming growth factor-beta1 is the predominant isoform required for breast cancer cell outgrowth in bone.

Mourskaia AA, Dong Z, Ng S, Banville M, Zwaagstra JC, O'Connor-McCourt MD, Siegel PM.

Oncogene. 2009 Feb 19;28(7):1005-15. doi: 10.1038/onc.2008.454. Epub 2008 Dec 15.

PMID:
19079339
6.

Analysis of the contribution of receptor subdomains to the cooperative binding and internalization of transforming growth factor-beta (TGF-beta) type I and type II receptors.

Zwaagstra JC, Collins C, Langlois MJ, O'Connor-McCourt MD.

Exp Cell Res. 2008 Aug 15;314(14):2553-68. doi: 10.1016/j.yexcr.2008.06.012. Epub 2008 Jun 19.

PMID:
18598696
7.

Identification of a functional site on the type I TGF-beta receptor by mutational analysis of its ectodomain.

Guimond A, Sulea T, Zwaagstra JC, Ekiel I, O'Connor-McCourt MD.

FEBS Lett. 2002 Feb 27;513(2-3):147-52.

9.
10.
11.

Similarities in regulation of the HSV-1 LAT promoter in corneal and neuronal cells.

Perng GC, Zwaagstra JC, Ghiasi H, Kaiwar R, Brown DJ, Nesburn AB, Wechsler SL.

Invest Ophthalmol Vis Sci. 1994 Jun;35(7):2981-9.

PMID:
8206716
12.

Type VIII adenylyl cyclase. A Ca2+/calmodulin-stimulated enzyme expressed in discrete regions of rat brain.

Cali JJ, Zwaagstra JC, Mons N, Cooper DM, Krupinski J.

J Biol Chem. 1994 Apr 22;269(16):12190-5.

13.

Molecular diversity in the adenylylcyclase family. Evidence for eight forms of the enzyme and cloning of type VI.

Krupinski J, Lehman TC, Frankenfield CD, Zwaagstra JC, Watson PA.

J Biol Chem. 1992 Dec 5;267(34):24858-62.

14.
15.

Activity of herpes simplex virus type 1 latency-associated transcript (LAT) promoter in neuron-derived cells: evidence for neuron specificity and for a large LAT transcript.

Zwaagstra JC, Ghiasi H, Slanina SM, Nesburn AB, Wheatley SC, Lillycrop K, Wood J, Latchman DS, Patel K, Wechsler SL.

J Virol. 1990 Oct;64(10):5019-28.

16.
17.

Supplemental Content

Loading ...
Support Center